Stay updated on Nusinersen Safety in SMA Clinical Trial

Sign up to get notified when there's something new on the Nusinersen Safety in SMA Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nusinersen Safety in SMA Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study record related to the safety and tolerability assessment of Nusinersen in participants with Spinal Muscular Atrophy (SMA). This change may reflect new information regarding the pharmacokinetics and long-term safety of Nusinersen in participants with SMA.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:49.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying genetic documentation and clinical signs of SMA, as well as additional inclusion and exclusion criteria. Previously, this section only indicated that no information was provided.
    Difference
    33%
    Check dated 2024-05-22T21:14:30.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:15:53.000Z thumbnail image

Stay in the know with updates to Nusinersen Safety in SMA Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nusinersen Safety in SMA Clinical Trial page.